TNFSF11 and chronic kidney disease: Second, we compared the impact of 2 different antiresorptive treatments, systemic blockade of RANKL and risedronate treatment, in mice with adenine-induced CKD on bone resorption/bone formation and cortical porosity after the development of porosity (study 2).